Canopy Growth Reports First Quarter Fiscal 2026 Financial Results

Canopy Growth Corporation (NASDAQ:CGC) is among the 12 Best Marijuana Stocks to Buy According to Analysts. Canopy Growth Corporation (NASDAQ:CGC) released Q1 FY2026 net revenue of $72.1M, up 9% year-over-year. This growth was fuelled by a 13% rise in medical cannabis sales and a 43% increase in adult-use cannabis sales in Canada to $27M. International cannabis revenue jumped 5% to $8.8 million, but Storz & Bickel vaporizer revenue decreased 25% to $15.1 million. The consolidated gross margin declined from 35% to 25% as a result of lower high-margin Poland sales and a shift toward higher-cost manufactured products. The net loss from continuing operations fell 21% to $23 million, while SG&A expenses fell 21% as part of $17 million in annualized cost savings obtained since March 2025. The amount of cash and short-term investments rose to $144 million.

CEO Luc Mongeau reported significant share growth in cannabis markets with high demand, while interim CFO Tom Stewart noted improving gross margins as a top target for FY2026. A new Storz & Bickel vaporizer is scheduled for introduction later in 2025. Canopy Growth Corporation (NASDAQ:CGC) anticipates that automation and increased PRJ production will boost margins in the second half. It is the Best Marijuana Stock.

While we acknowledge the potential of CGC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.